Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2006;47:762-770
Published online before print February 27, 2006, doi: 10.1161/01.HYP.0000208299.62535.58
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
47/4/762    most recent
01.HYP.0000208299.62535.58v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pokreisz, P.
Right arrow Articles by Janssens, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pokreisz, P.
Right arrow Articles by Janssens, S.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Other hypertension
Right arrow Pulmonary circulation and disease
Right arrow Remodeling
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology
Right arrow Smooth muscle proliferation and differentiation

(Hypertension. 2006;47:762.)
© 2006 American Heart Association, Inc.


Original Articles

Cytochrome P450 Epoxygenase Gene Function in Hypoxic Pulmonary Vasoconstriction and Pulmonary Vascular Remodeling

Peter Pokreisz; Ingrid Fleming; Ladislau Kiss; Eduardo Barbosa-Sicard; Beate Fisslthaler; John R. Falck; Bruce D. Hammock; In-Hae Kim; Zsolt Szelid; Pieter Vermeersch; Hilde Gillijns; Marijke Pellens; Friedrich Grimminger; Anton-Jan van Zonneveld; Desire Collen; Rudi Busse; Stefan Janssens

From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute of Biotechnology (P.P., Z.S., P.V., H.G., M.P., D.C., S.J.) and Cardiac Unit (S.J.), University of Leuven, Belgium; Department of Internal Medicine (L.K., F.G.), Justus-Liebig-University, Giessen, Germany; Institute of Cardiovascular Physiology (I.F., E.B.-S., B.F., R.B.), Johann Wolfgang Goethe University, Frankfurt am Main, Germany; Departments of Biochemistry and Pharmacology (J.R.F.), University of Texas Southwestern Medical Center, Dallas; Department of Entomology and Cancer Research Center (B.D.H., I.-H.K.), University of California, Davis; and Department of Nephrology (A.-J.v.Z.), Leiden University Medical Center, Leiden, the Netherlands.

Correspondence to Stefan Janssens, Center for Transgene Technology and Gene Therapy, Campus Gasthuisberg, University of Leuven, 49, Herestraat, B-3000 Leuven, Belgium. E-mail Stefan.janssens{at}med.kuleuven.ac.be

We assessed pulmonary cytochrome P450 (CYP) epoxygenase expression and activity during hypoxia and explored the effects of modulating epoxygenase activity on pulmonary hypertension. The acute hypoxic vasoconstrictor response was studied in Swiss Webster mice, who express CYP2C29 in their lungs. Animals were pretreated with vehicle, the epoxygenase inhibitor (N-methylsulfonyl-6-[2-propargyloxyphenyl] hexanamide) or an inhibitor of the soluble epoxide hydrolase. Whereas the epoxygenase inhibitor attenuated hypoxic pulmonary constriction (by 52%), the soluble epoxide hydrolase inhibitor enhanced the response (by 39%), indicating that CYP epoxygenase-derived epoxyeicosatrienoic acids elicit pulmonary vasoconstriction. Aerosol gene transfer of recombinant adenovirus containing the human CYP2C9 significantly elevated mean pulmonary artery pressure and total pulmonary resistance indices, both of which were sensitive to the inhibitor sulfaphenazole. The prolonged exposure of mice to hypoxia increased CYP2C29 expression, and transcript levels increased 5-fold after exposure to normobaric hypoxia (FIO2 0.07) for 2 hours. This was followed by a 2-fold increase in protein expression and by a significant increase in epoxyeicosatrienoic acid production after 24 hours. Chronic hypoxia (7 days) elicited pulmonary hypertension and pulmonary vascular remodeling, effects that were significantly attenuated in animals continually treated with N-methylsulfonyl-6-[2-propargyloxyphenyl] hexanamide (–46% and –55%, respectively). Our results indicate that endogenously generated epoxygenase products are associated with hypoxic pulmonary hypertension in mice and that selective epoxygenase inhibition significantly reduces acute hypoxic pulmonary vasoconstriction and chronic hypoxia-induced pulmonary vascular remodeling. These observations indicate potential novel targets for the treatment of pulmonary hypertension and highlight a pivotal role for CYP epoxygenases in pulmonary responses to hypoxia.


Key Words: endothelium-derived factors • arachidonic acids • endothelium-derived factors • lung • remodeling




This article has been cited by other articles:


Home page
IOVSHome page
U. R. Michaelis, N. Xia, E. Barbosa-Sicard, J. R. Falck, and I. Fleming
Role of Cytochrome P450 2C Epoxygenases in Hypoxia-Induced Cell Migration and Angiogenesis in Retinal Endothelial Cells
Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1242 - 1247.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
P. Pokreisz, G. Marsboom, and S. Janssens
Pressure overload-induced right ventricular dysfunction and remodelling in experimental pulmonary hypertension: the right heart revisited
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H75 - H84.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Vermeersch, E. Buys, P. Pokreisz, G. Marsboom, F. Ichinose, P. Sips, M. Pellens, H. Gillijns, M. Swinnen, A. Graveline, et al.
Soluble Guanylate Cyclase-{alpha}1 Deficiency Selectively Inhibits the Pulmonary Vasodilator Response to Nitric Oxide and Increases the Pulmonary Vascular Remodeling Response to Chronic Hypoxia
Circulation, August 21, 2007; 116(8): 936 - 943.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Ai, Y. Fu, D. Guo, H. Tanaka, N. Wang, C. Tang, B. D. Hammock, J. Y.-J. Shyy, and Y. Zhu
Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo
PNAS, May 22, 2007; 104(21): 9018 - 9023.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. T. Moreland, J. D. Procknow, R. S. Sprague, J. L. Iverson, A. J. Lonigro, and A. H. Stephenson
Cyclooxygenase (COX)-1 and COX-2 Participate in 5,6-Epoxyeicosatrienoic Acid-Induced Contraction of Rabbit Intralobar Pulmonary Arteries
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 446 - 454.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F.-R. E. Curry and C. A. Glass
TRP Channels and the Regulation of Vascular Permeability: New Insights From the Lung Microvasculature
Circ. Res., October 27, 2006; 99(9): 915 - 917.
[Full Text] [PDF]